netFormulary
 Report : A-Z NHS England items in Formulary 05/08/2021 17:54:17
[Back]
 
Section Status NHS England Name
08.01.05 Restricted Use MHS England Abemaciclib 50mg, 100mg, 150mg 
08.01.05 Restricted Use MHS England Alectinib 150mg Alecensa®
08.01.05 Restricted Use MHS England Arsenic Trioxide Trisenox®
08.01.05 Restricted Use MHS England Atezolizumab 1200mg/20mg 
08.01.05 Restricted Use MHS England Avelumab 200mg/10mL 
08.01.05 Restricted Use MHS England Axitinib 1mg, 3mg, 5mg, 7mg 
03.04.02 Restricted Use MHS England Benralizumab 30mg/mL 
05.03.01 Restricted Use MHS England Bictegravir/Emtricitabine/Tenofovir 50mg/200mg/25mg (Biktarvy®) Biktarvy®
08.01.05 Restricted Use MHS England Binimetinib 50mg, 75mg 
08.01.05 Restricted Use MHS England Brigatinib 30mg, 60mg, 90mg 
08.01.05 Restricted Use MHS England Cabozantinib 20mg, 40mg, 60mg 
08.01.05 Restricted Use MHS England Carfilzomib 10mg, 30mg, 60mg  
08.01.05 Restricted Use MHS England Crizotinib 200mg,250mg Xalkori®
08.01.05 Restricted Use MHS England Dabrafenib 50mg, 75mg  
08.02.03 Restricted Use MHS England Dinutuximab beta 4.5mg/mL Qarziba®
08.01.05 Restricted Use MHS England Encorafenib 50mg, 75mg 
08.01.05 Restricted Use MHS England Gemtuzumab ozogamicin 5mg 
08.02.04 Restricted Use MHS England Glatiramer Acetate 20mg/1mL, 40mg/1mL Copaxone®
08.01.05 Restricted Use MHS England Ibrutinib 140mg 
08.01.05 Restricted Use MHS England Inotuzumab ozogamicin 1mg Besponsa®
08.02.04 Restricted Use MHS England Interferon Beta-1a 6 million units, 22 micrograms/0.5mL Rebif®
08.02.04 Restricted Use MHS England Interferon Beta-1a 6million units, 30micrograms/0.5mL Avonex®
08.02.04 Restricted Use MHS England Interferon Beta-1b 9.6million units (300micrograms) Extavia®
05.02.01 Formulary MHS England Isavuconazole 
05.02.01 Formulary MHS England Isavuconazole 200mg  
08.02.04 Restricted Use MHS England Lenalidomide 1.5mg, 5mg, 7.5mg, 10mg, 15mg, 25mg 
08.01.05 Restricted Use MHS England Lenvatinib 4mg, 10mg 
08.01.05 Restricted Use MHS England Liposomal cytarabine-daunorubicin 44mg/100mg Vyxeos®
08.01.05 Restricted Use MHS England Lutetium (177Lu) oxodotreotide Lutathera®
08.01.05 Restricted Use MHS England Midostaurin 25mg Rydapt®
08.02.04 Restricted Use MHS England Natalizumab 300mg/15mL 
08.01.05 Restricted Use MHS England Nivolumab 40mg/4mL, 100mg/10mL 
08.02.03 Restricted Use MHS England Obinutuzumab 1000mg/40mL 
08.01.01 Restricted Use MHS England Ocrelizumab 300mg Ocrevus®
08.02.03 Restricted Use MHS England Ofatumumab 100mg, 1000mg 
08.02.03 Restricted Use MHS England Pembrolizumab 100mg/4mL 
08.02.03 Restricted Use MHS England Pembrolizumab 50mg 
08.01.05 Restricted Use MHS England Pertuzumab 420mg/14ml 
08.01.05 Restricted Use MHS England Regorafenib 40mg 
08.03.04.01 Restricted Use MHS England Ribociclib 200mg 
08.01.05 Restricted Use MHS England Sorafenib 200mg 
08.01.05 Restricted Use MHS England Tivozanib 890micrograms, 1340micrograms Fotivda®
06.05.02 Restricted Use MHS England Tolvaptan 15mg, 30mg Samsca®
08.01.05 Formulary MHS England Trametinib 0.5mg, 2mg  
08.01.05 Restricted Use MHS England Trastuzumab emtansine 100mg, 160mg 
08.01.05 Restricted Use MHS England Venetoclax 10mg, 50mg, 100mg 
Buckinghamshire Formulary